Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 324 clinical trials
None
Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help

neutrophil count
metastatic renal cell carcinoma
hypertension
carcinoma in situ
monoclonal antibodies
  • 17 views
  • 07 Nov, 2020
  • 2 locations
None
Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer

The objective is to investigate the efficacy and safety of raltitrexed-based chemotherapy plus bevacizumab in the treatment of advanced colorectal cancer

  • 5 views
  • 05 Sep, 2021
  • 4 locations
None
Nab-paclitaxel Combined With Bevacizumab in the Treatment of Metastatic Neuroendocrine Carcinoma

This is an open-label, phase II study evaluating efficacy and safety of Nab-paclitaxel Combined With Bevacizumab for unresectable Recurrent or metastatic neuroendocrine carcinoma.

  • 0 views
  • 31 Jan, 2021
  • 1 location
None
Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene

This prospective phase II study is determined to explore the efficacy and safety of radiotherapy and bevacizumab maintenance therapy for oligometastatic lung adenocarcinoma with negative driver

  • 0 views
  • 22 Jan, 2021
  • 1 location
None
A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer

The objective is to investigate the efficacy and safety of two-weekly alternative regimen of Bevacizumab plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer.

  • 0 views
  • 07 Sep, 2021
  • 1 location
None
Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC

Toripalimab (hereafter referred to as JS001) combined with Bevacizumab versus Sorafenib as the first-line therapy for advanced HCC This study will enroll the patients with locally advanced or metastatic

  • 0 views
  • 03 Feb, 2021
  • 1 location
None
5FU/LV Irinotecan Temozolomide and Bevacizumab for MGMT Silenced Microsatellite Stable Metastatic Colorectal Cancer.

antiangiogenic blockade with bevacizumab significantly improved survival. No biomarkers are available for predicting sensitivity/resistance to single chemotherapeutic drugs, the simultaneous delivery of all

  • 1 views
  • 01 Mar, 2021
  • 1 location
None
Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer

This phase III trial studies how well vitamin D3 given with standard chemotherapy and bevacizumab works in treating patients with colorectal cancer that has spread to other parts of the body

neutrophil count
liver metastasis
cancer treatment
adjuvant therapy
measurable disease
  • 89 views
  • 22 Nov, 2021
  • 980 locations
None
FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC

FOLFIRI in case of toxicity. Standard arm A: The patient will be treated with FOLFOXIRI plus bevacizumab for up to 12 cycles (24 weeks) or until progression (if the latter occurs before

neutrophil count
liver metastasis
serum bilirubin level
BRAF
fluoropyrimidine
  • 1 views
  • 23 Jan, 2021
  • 1 location
None
TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab

This is a phase II, open-Label clinical trial to evaluate the safety and efficacy of TTAC-0001 in patients with recurrent glioblastoma who was progressed on bevacizumab including therapy.

karnofsky performance status
neutrophil count
bevacizumab
gliosarcoma
glioblastoma multiforme
  • 4 views
  • 26 Sep, 2021
  • 3 locations